If you would like more information on Liver, Bile Duct and Gallbladder Cancer Clinical Trials offered at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, please contact: 410-955-8964, Option #2.
Current trial listing:
Hepatocellular Carcinoma
J17189 - Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab (MEDI 4736) in Patients with Advanced Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, and Cholangiocarcinoma/Gallbladder Cancer
NCT03257761
J18118 - The effect of CTLA4/PDL-1 Blockade following drug-eluting bead transarterial chemoembolization (DEB-TACE) in patients with intermediate stage of HCC using Durvalumab (MEDI4736) and Tremelimumab
NCT03638141
J19140 - A pilot study of a DNAJB1-PRKACA fusion kinase peptide vaccine combined with Nivolumab and Ipilimumab for patients with fibrolamellar hepatocellular carcinoma
NCT04248569
J2003 - An Open-label, Multi-center, Phase I/IIa Study of a Personalized Neoantigen DNA Vaccine (GNOS-PV02) and Plasmid encoded IL 12 (INO-9012) in Combination with Pembrolizumab (MK-3475) in Subjects with Advanced Hepatocellular Carcinoma
NCT04251117
J2007 - A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination with Systemic Anti-Cancer Therapies in Subjects with Advanced Solid Tumors
NCT03829436
Coming Soon:
J19132 - A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma
NCT04039607
Biliary Tract Cancers: Cholangiocarcinoma/Bile duct Cancer/Gallbladder Cancer
J18160 - A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)
NCI03656536
J18164 - A Phase II basket study of the oral selective pan-FGFR inhibitor Debio 1347 in subjects with solid tumors harboring a fusion of FGFR1, FGFR2 or FGFR3 (Debio 1347-201)
NCT03834220
J19108 - A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without M7824 (bintrafusp alfa) as First-line Treatment of Biliary Tract Cancer
NCT04066491
NCTNS1815 - S1815 - A Phase III Randomized Trial of Gemcitabine, Cisplatin and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
NCT03768414
ETCTN10129 - A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors.
NCT03212274
ETCTN10222 - A Phase II study of olaparib and AZD6738 in isocitrate dehydrogenase (IDH) mutant solid tumors.
NCT03878095
J2007 - A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination with Systemic Anti-Cancer Therapies in Subjects with Advanced Solid Tumors
NCT03829436